GlycoMimetics (NASDAQ:GLYC) Announces Earnings Results, Beats Estimates By $0.01 EPS

GlycoMimetics (NASDAQ:GLYC) announced its earnings results on Wednesday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01, Zacks reports.

GlycoMimetics Trading Up 4.5%

Shares of NASDAQ GLYC opened at $0.25 on Friday. GlycoMimetics has a one year low of $0.14 and a one year high of $0.63. The firm has a market capitalization of $16.12 million, a PE ratio of -0.42 and a beta of 1.70. The business has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.28.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GLYC shares. StockNews.com began coverage on shares of GlycoMimetics in a research report on Friday, May 9th. They set a “sell” rating for the company. Cantor Fitzgerald initiated coverage on shares of GlycoMimetics in a report on Friday, March 21st. They set an “overweight” rating for the company.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.